Clinical application of first line anti-tuberculous drug susceptibility test by phage amplified biologically assay

( views:270, downloads:0 )
Author:
SHA Wei(Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital, Shanghai 200433, China)
WANG fie(Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital, Shanghai 200433, China)
HU Zhong-yi(Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital, Shanghai 200433, China)
XIAO He-ping(Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital, Shanghai 200433, China)
TANG Shen-jie(Shanghai Key Laboratory of Mycobacterium Tuberculosis, Shanghai Pulmonary Hospital, Shanghai 200433, China)
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
Volume 04, Issue 05, 2011
DOI:
10.3760/cma.j.issn.1674-2397.2011.05.006
Key Word:
Mycobacteriophages;Pulmonary tuberculosis;Drug susceptibility;Chemotherapy regimen

Abstract: Objective To evaluate clinical application of phage amplified biologically assay (PhaB) in susceptibility test of Mycobacterium tuberculosis (MTB) in sputum. Methods The drug susceptibility of MTB was detected by PhaB in 143 patients with sputum-positive pulmonary tuberculosis (PTB),and the chemotherapy regimens were adjusted according to the results of susceptibility test.Independent samples t-tests were used for comparison of means.Count numbers were compared with Chisquare test.If there were count number of 0,Fisher probabilities should be used.Results The total positive rate of PhaB was 94.4% (135/143) with no differences between three types of PTB (x2 =1.886,P > 0.05 ).The duration of testing for PhaB group was (6.6 ± 1.8) days,while for control was (29.4 ±8.7) days (t =29.01,P < 0.01 ).Compared with control group,the 2-month negative-conversion rate (63.2% vs.35.1%,x2 =3.989,P < 0.05 ) and cure rate ( 100% vs.78.4%,P < 0.05 ) of PhaB group in type Ⅱ patients were significantly higher.But there were no differences between PhaB and control groups in type Ⅰ and Ⅲ PTB patients.Conclusion The results of PhaB drug susceptibility test can be helpful for choosing effective chemotherapy regimen for PTB patients rapidly.

  • [1]王洁,崔振玲,胡忠义,等.噬菌体法同时检测四种一线抗结核药物耐药性.中华传染病杂志,2006,24(2):102-105.
  • [2]中华医学会结核病学分会.肺结核诊断和治疗指南.中华结核和呼吸杂志,2001,24(2):70-74.
  • [3]胡忠义,倪莲娣,靳安佳,等.噬菌体生物扩增法快速检测结核分枝杆菌方法学研究.中华结核和呼吸杂志,2004,27(12):801-805.
  • [4]靳安佳,王洁,胡忠义,等.噬菌体生物扩增法检测肺结核患者痰样本临床应用研究.中华检验医学杂志,2005,28(8):807-808.
  • [5]中国防痨协会.耐多药结核病化学治疗的意见(试行).中国防痨杂志,2003,25:4-9.
  • [6]范玉美,肖和平.梅建.上海市首次复治肺结核患者的耐药分析.中华结核和呼吸杂志,2006,29(10):698-701.
  • [7]肖和平.中国耐药结核病的流行现状与治疗对策.中华结核和呼吸杂志,2010,33(7):481-482.
  • [8]谢士达,刘成永,张凤池,等.利用噬菌体生物扩增法快速检测痰样本中结核分支杆菌.临床肺科杂志,2007,12(8):789-790.
  • [9]胡忠义.噬菌体生物扩增法检测结核分枝杆菌及其耐药性方法评价.中华检验医学杂志,2007,30(7):821-823.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn